Skip to content
Find a Provider
Jainulabdeen J. Ifthikharuddin, M.D.

Jainulabdeen J. Ifthikharuddin, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 273-1042
Administrative (585) 276-3355

About Me

As an oncologist, my goal is to deliver high-quality, comprehensive and compassionate care that is suited to each patient's unique needs.

I have a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. In addition to my clinical and teaching responsibilities, ...
As an oncologist, my goal is to deliver high-quality, comprehensive and compassionate care that is suited to each patient's unique needs.

I have a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. In addition to my clinical and teaching responsibilities, I am an active participant in several myeloma-related clinical trials.

Conditions I Treat

- Myeloma
- Monoclonal gammopathies
- Amyloidosis

Professional Background

Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematol...
Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematology (MRC Path). He subsequently completed residency training in Internal Medicine and fellowship in Hematology/Oncology at The University of Rochester and joined the faculty in the year 2000. He is board certified in Hematology. In addition to clinical and teaching responsibilities, he is an active participant in several clinical trials.

Languages

English, Hindi, Tamil, Urdu

Faculty Appointments

Professor of Clinical Medicine - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 1996 - 1999

Residency, Internal Medicine, University of Rochester Medical Center. 1994 - 1996

Internship, Madras Medical College And Government General Hospital (India). 1985 - 1986

Education

MBBS | Madras Medical College (India). 1985

Awards

Best Teacher Award. 2004

AMGEN Fellowship Grant. 1999

Strong Memorial Hospital Innovative Improvement Program. 1997

Ad hoc manuscript reviewer.

Ad hoc manuscript reviewer.

Research

Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematol...
Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematology (MRC Path). He subsequently completed residency training in Internal Medicine and fellowship in Hematology/Oncology at The University of Rochester and joined the faculty in the year 2000. He is board certified in Hematology. In addition to clinical and teaching responsibilities, he is an active participant in several clinical trials.

Publications

Journal Articles

A phase I study of decitabine and rapamycin in relapsed/refractory AML

Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikaruddin JJ, Mulford D, Chen R, Bechelli J, Roswell K, Minhajuddin M, Jordan CT, Phillips Gl 2nd.

Leukemia Research. 2013; 37(12): 1662-7.

Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease

Milner LA; Becker MW; Bernstein SH; Bruckner L; Friedberg JW; Holland GA; Ifthikharuddin JJ; LIesveld JL; Mathes EJ; Mechel HL; Mullen CA; Sasson T; Phillips GL 2nd.

Am J Hematology. 2011; 86(8): 712-714.

Proteasome inhibition in myelodysplastic syndromes and acute myelogeneous leukemia cell lines

Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips GL 2nd.

Cancer Invest. 2011; 29(7): 438-450.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (g-CSF) (CLAG regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker,AR; Komrokji, RS; Ifthikharuddin, JJ; Messina, P; Mulford, D; Becker, M; Friedberg, J; Oliva, J; Phillips, G; Liesveld, JL; Abboud, C.

Leukemia Research. 2008; 12(32): 1830-1836.

A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection

Phillips GL 2nd; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW.

Leuk Res. 2008; 32(12): 1830-1836.

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.

Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, Abboud CN, Sanz I, Huggins J

Blood.. 2006 April 1107 (7):2895-903. Epub 12/20/2005.

Extracorporeal photopheresis, Pentostatin and TBI for reduced intensity preparation: Adaptation of the Tufts experience at a single transplant center.

Liesveld,J. L.; Abboud,C. N.; Bernstein,S. S.; Friedberg,J.; Ifthikharuddin,J. J.; Constine,L. S.; Kaplan,K. L.; Wedow,L. A.; Nichols,D. D.; Oliva,J.; Etter,M.; Phillips,G. L. II;.

Blood. 2005; 106(11): 440B.

Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.

Dib, E.; Ifthikharuddin, J.J.; Scott, G. A.; Partilo, S.R.

Leukemia Research. 2005; 20: 233-234.

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH

Seminars in oncology.. 2004 December 31 (6 Suppl 18):59-61. Epub 1900 01 01.

Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review.

Komrokji R, Ifthikharuddin JJ, Felgar RE, Abboud CN, Wedow LA, Connaughton A, Bennett JM

American journal of hematology.. 2004 August 76 (4):389-94. Epub 1900 01 01.

Use of imatinib mesylate in CML patients autografted in the pre-imatinib era: A single center experience.

Liesveld,J. L.; Nichols,D.; Ifthikharuddin,J. J.; Lancet,J. E.; Abboud,C. N.;.

Blood. 2002; 100(11): 473B.

Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation.

Fu SQ, Abboud CN, Brennan JK, Ifthikharuddin JJ, Nichols D, Liesveld JL

Blood cells, molecules & diseases.. 2002 28 (3):315-21. Epub 1900 01 01.

Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.

Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2002 8 (12):662-5. Epub 1900 01 01.

2-Chlorodeoxyadenosine (2-CDA) with weekly rituximab and granulocyte-macrophage stimulating factor (GM-CSF): A highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD).

Shah,P. K.; Ifthikharuddin,J. J.; Mintz,M.; Felgar,R.; Liesveld,J.; Abboud,C.;.

Blood. 2001; 98(11): 249b.

Rituximab and cladribine (2-CDA): In-vivo synergistic activity in B-cell lymphoproliferative disorders (BLPD) expressing the CD20 antigen.

Shah, P.; Ifthikharuddin, J.J.; Mintz, M.; Felgar, R.; Liesveld, J.; Abboud, C;.

Proc. ASCO. 2001; 20(2): 228b.

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.

Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM

American journal of hematology.. 2000 October 65 (2):171-3. Epub 1900 01 01.

CD-20 expression in post-transplant lymphoproliferative disorders (PTLD): Treatment with Rituximab

Ifthikharuddin,J. J.; Mieles,L. A.; Rosenblatt,J. D.; Ryan,C. K.; Sahasrabudhe,D. M.;.

Blood. 1999; 94(1): 248b.

Isolated splenic blastic transformation of idiopathic myelofibrosis and response to splenectomy.

Ifthikharuddin JJ, Janas J, Phatak PD

Leukemia research.. 1997 March 21 (3):255-7. Epub 1900 01 01.

Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders.

Lim SH, Ifthikharuddin JJ

Leukemia & lymphoma.. 1994 September 15 (1-2):61-4. Epub 1900 01 01.

Clostridium perfringens septicaemia and massive intravascular haemolysis as a terminal complication of autologous bone marrow transplant.

Ifthikharuddin, J.J.; Holmes, J.A.

Clinical & Laboratory Haematology. 1992; 14(2): 159-61.

Books

Principles and Practice of Infectious Diseases (1999)

Chapter: Introduction-Type C oncoviruses including human T-cell lymphotropic types I and II

Authors: Ifthikharuddin, JJ; Rosenblatt, JD

Publisher: Churchill Livingston, New York 1999